FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379649977> ?p ?o ?g. }

• W4379649977 endingPage "901" @default.
• W4379649977 startingPage "901.1" @default.
• W4379649977 abstract "Background Complete renal response (CRR) defined by ACR/EULAR guidelines is a desirable clinical outcome associated with long-term preservation of kidney function in patients with lupus nephritis (LN) as demonstrated in clinical trials when achieved after 1-2 years. Urinary CD163 (uCD163), a biomarker that correlates with LN histologic inflammation, has been observed to predict clinical response to therapy [1] . Results previously reported on MISSION, a Phase 2 open-label study evaluating the safety and tolerability of zetomipzomib in active, proliferative LN, demonstrated clinically meaningful renal responses along with reductions in uCD163 and strong correlation with UPCR [2] . Decrease in uCD163 at early timepoints and its prediction in proteinuria response may increase probability of achieving a meaningful treatment effect. Objectives Data from the MISSION Phase 2 study of zetomipzomib was used to evaluate uCD163 as a potential predictor of complete renal response (CRR) for patients with LN. Methods In the MISSON Phase 2 study, patients with active proliferative LN (Class III or IV ± V) received 60 mg of zetomipzomib subcutaneously once weekly (first dose 30 mg) in addition to stable background therapy for 24 weeks. End-of-treatment (EOT) was at Week (W) 25, and end-of-study (EOS) occurred at W37. uCD163 data at W13 and W25 were used to model a predictive association with CRR* at W25 & W37, respectively. A logistic regression model and the Youden Index were used to generate Receiver Operating Characteristics (ROC) curves to help evaluate accuracy and identify optimal cut-off points to differentiate responders and non-responders. *Complete Renal Response: UPCR ≤0.5, eGFR ≥60 mL/min/1.73m 2 or no worsening of eGFR from baseline of ≥25%, prednisone (or equivalent) ≤10 mg and no use of prohibited medication. Results Of the 21 patients enrolled in MISSION, 17 reached EOT and EOS. CRR was achieved in 35% and 41% of patients at W25 and W37. Anti-inflammatory potential of zetomipzomib was demonstrated by reduction of uCD163, which was strongly correlated with UPCR improvement at W13, W25 and W37 (Figure 1). For the thirteen patients who consented to urine biomarker analysis, baseline 24-hour UPCR was: mean=2.8 mg/mg, median=1.8 mg/mg, SD=3.3, range 0.93-13.4; uCD163: mean=1.7 mg/mmol, median=0.97 mg/mmol, SD=2.3, range 0.28, 8.9. ROC analysis results from the MISSION study suggests that LN patients with uCD163 values of ≤0.13 at W13 and ≤0.09 at W25 are more likely to achieve a CRR at W25 and W37 following treatment with zetomipzomib (Table 1). Conclusion This post-hoc analysis of zetomipzomib data generated from the MISSION Ph2 study suggests that in patients with proliferative LN, uCD163 levels might predict CRR achieved up to 3 months later and could therefore potentially help to guide optimal therapy. Further evidence is needed from larger randomized LN trials with zetomipzomib to confirm the utility and limits of uCD163 as a predictive biomarker. Reference [1]Mejia Vilet et al, JASN 2020; 2 Parikh SV et al, ASN 2022. Figure 1. uCD163 and UPCR Correlation Plots Table 1. Summary of ROC Analysis based on Logistic Regression Model Predictor Outcome N used in ROC analysis Youden Cutpoint ROC AUC (max=1) Sensitivity (0-1) Specificity (0-1) Predictive probability in CRR Predictive probability in non-CRR uCD163 at Week 13 (p=0.3615) CRR at Week 25 (4 CRR) 12 (1 missing) uCD163 =0.13 1.0 1.0 1.0 100% 100% uCD163 at Week 25 (p=0.1218) CRR at Week 37 (5 CRR) 13 uCD163 =0.09 0.8 0.6 1.0 100% 80% uCD163 =0.56* 0.8 0.75 67% 86% *based on the criterion of smallest Δ=Sensitivity – Specificity. Acknowledgements: NIL. Disclosure of Interests Joan T Merrill Consultant of: AbbVie, Alexion, Alumis, Amgen, Astra Zeneca, Aurinia, Bristol Myers Squibb, EMD Serono, Genentech, Gilead, GlaxoSmithKline, Lilly, Merck, Pfizer, Provention, Remegen, Sanofi, UCB, and Zenas, Grant/research support from: Astra Zeneca, Bristol Myers Squibb, and GlaxoSmithKline, Richard Leff Shareholder of: Kezar Life Sciences, Consultant of: Kezar Life Sciences, Andrea Fan Shareholder of: Kezar Life Sciences, Employee of: Full time employee of Kezar Life Sciences, Kiruthi Palaniswamy Shareholder of: Kezar Life Sciences, Employee of: Full time employee of Kezar Life Sciences, Noreen Henig Shareholder of: Kezar Life Sciences, Employee of: Chief Medical Officer at Kezar Life Sciences, Steven Hua Shareholder of: Kezar Life Sciences, Employee of: Full time employee of Kezar Life Sciences." @default.
• W4379649977 created "2023-06-08" @default.
• W4379649977 creator A5010712376 @default.
• W4379649977 creator A5013054661 @default.
• W4379649977 creator A5046988690 @default.
• W4379649977 creator A5052053321 @default.
• W4379649977 creator A5061620538 @default.
• W4379649977 creator A5074329004 @default.
• W4379649977 date "2023-05-30" @default.
• W4379649977 modified "2023-09-23" @default.
• W4379649977 title "POS1143 URINARY CD163 PREDICTS COMPLETE RENAL RESPONSE WITH ZETOMIPZOMIB TREATMENT IN THE OPEN-LABEL MISSION PHASE 2 STUDY IN PATIENTS WITH LUPUS NEPHRITIS" @default.
• W4379649977 doi "https://doi.org/10.1136/annrheumdis-2023-eular.2695" @default.
• W4379649977 hasPublicationYear "2023" @default.
• W4379649977 type Work @default.
• W4379649977 citedByCount "0" @default.
• W4379649977 crossrefType "journal-article" @default.
• W4379649977 hasAuthorship W4379649977A5010712376 @default.
• W4379649977 hasAuthorship W4379649977A5013054661 @default.
• W4379649977 hasAuthorship W4379649977A5046988690 @default.
• W4379649977 hasAuthorship W4379649977A5052053321 @default.
• W4379649977 hasAuthorship W4379649977A5061620538 @default.
• W4379649977 hasAuthorship W4379649977A5074329004 @default.
• W4379649977 hasBestOaLocation W43796499771 @default.
• W4379649977 hasConcept C126322002 @default.
• W4379649977 hasConcept C126894567 @default.
• W4379649977 hasConcept C143998085 @default.
• W4379649977 hasConcept C151956035 @default.
• W4379649977 hasConcept C159641895 @default.
• W4379649977 hasConcept C185592680 @default.
• W4379649977 hasConcept C197934379 @default.
• W4379649977 hasConcept C2778375690 @default.
• W4379649977 hasConcept C2779134260 @default.
• W4379649977 hasConcept C2779561371 @default.
• W4379649977 hasConcept C2779912601 @default.
• W4379649977 hasConcept C2780091579 @default.
• W4379649977 hasConcept C2781197716 @default.
• W4379649977 hasConcept C31760486 @default.
• W4379649977 hasConcept C535046627 @default.
• W4379649977 hasConcept C55493867 @default.
• W4379649977 hasConcept C58471807 @default.
• W4379649977 hasConcept C71924100 @default.
• W4379649977 hasConcept C77411442 @default.
• W4379649977 hasConceptScore W4379649977C126322002 @default.
• W4379649977 hasConceptScore W4379649977C126894567 @default.
• W4379649977 hasConceptScore W4379649977C143998085 @default.
• W4379649977 hasConceptScore W4379649977C151956035 @default.
• W4379649977 hasConceptScore W4379649977C159641895 @default.
• W4379649977 hasConceptScore W4379649977C185592680 @default.
• W4379649977 hasConceptScore W4379649977C197934379 @default.
• W4379649977 hasConceptScore W4379649977C2778375690 @default.
• W4379649977 hasConceptScore W4379649977C2779134260 @default.
• W4379649977 hasConceptScore W4379649977C2779561371 @default.
• W4379649977 hasConceptScore W4379649977C2779912601 @default.
• W4379649977 hasConceptScore W4379649977C2780091579 @default.
• W4379649977 hasConceptScore W4379649977C2781197716 @default.
• W4379649977 hasConceptScore W4379649977C31760486 @default.
• W4379649977 hasConceptScore W4379649977C535046627 @default.
• W4379649977 hasConceptScore W4379649977C55493867 @default.
• W4379649977 hasConceptScore W4379649977C58471807 @default.
• W4379649977 hasConceptScore W4379649977C71924100 @default.
• W4379649977 hasConceptScore W4379649977C77411442 @default.
• W4379649977 hasIssue "Suppl 1" @default.
• W4379649977 hasLocation W43796499771 @default.
• W4379649977 hasOpenAccess W4379649977 @default.
• W4379649977 hasPrimaryLocation W43796499771 @default.
• W4379649977 hasRelatedWork W2087572179 @default.
• W4379649977 hasRelatedWork W2349737464 @default.
• W4379649977 hasRelatedWork W2973351425 @default.
• W4379649977 hasRelatedWork W3020904527 @default.
• W4379649977 hasRelatedWork W3029009186 @default.
• W4379649977 hasRelatedWork W3083874951 @default.
• W4379649977 hasRelatedWork W3185351247 @default.
• W4379649977 hasRelatedWork W4205614333 @default.
• W4379649977 hasRelatedWork W4280585233 @default.
• W4379649977 hasRelatedWork W593504957 @default.
• W4379649977 hasVolume "82" @default.
• W4379649977 isParatext "false" @default.
• W4379649977 isRetracted "false" @default.
• W4379649977 workType "article" @default.